GlaxoSmithKline GSK and Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced an agreement for the development and commercialization of IPX066 outside the United States and Taiwan.
IPX066, an investigational product under development for the treatment of Parkinson's Disease, is currently in Phase III clinical trials.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
